Journal article

Functional interdependence of BRD4 and DOT1L in MLL leukemia

Omer Gilan, Enid YN Lam, Isabelle Becher, Dave Lugo, Ester Cannizzaro, Gerard Joberty, Aoife Ward, Meike Wiese, Chun Yew Fong, Sarah Ftouni, Dean Tyler, Kym Stanley, Laura MacPherson, Chen-Fang Weng, Yih-Chih Chan, Margherita Ghisi, David Smil, Christopher Carpenter, Peter Brown, Neil Garton Show all

Nature Structural & Molecular Biology | NATURE PUBLISHING GROUP | Published : 2016

Grants

Awarded by National Health and Medical Research Council of Australia


Awarded by AbbVie


Awarded by Bayer


Awarded by Lilly Canada


Awarded by Novartis Research Foundation


Awarded by Ontario Ministry of Economic Development and Innovation


Awarded by Pfizer


Awarded by Takeda


Awarded by Wellcome Trust


Awarded by Boehringer Ingelheim


Awarded by Genome Canada through the Ontario Genomics Institute


Awarded by GlaxoSmithKline


Awarded by Cancer Research UK


Awarded by Medical Research Council


Awarded by Worldwide Cancer Research


Funding Acknowledgements

A postdoctoral Fellowship awarded to O.G. from Leukaemia Foundation Australia partly supported this work. A mid-career Fellowship awarded to E.Y.N.L. from the Victoria Cancer Agency partly supported this work. A Senior Leukaemia Foundation Australia Fellowship and VESKI Innovation Fellowship currently support M.A.D. The National Health and Medical Research Council of Australia (1066545 (M.A.D.), 1085015 (M.A.D.), 1106444 (M.A.D.)) and Leukaemia Foundation Australia fund M.A.D.'s laboratory. This work was also funded in part by the Structural Genomics Consortium, a registered charity (no. 1097737) that received funds from AbbVie; Bayer; Boehringer Ingelheim; Genome Canada through the Ontario Genomics Institute (OGI-055); GlaxoSmithKline; Janssen; Lilly Canada; the Novartis Research Foundation; the Ontario Ministry of Economic Development and Innovation; Pfizer; Takeda; and the Wellcome Trust (092809/Z/10/Z).